Cite
HARVARD Citation
Haslam, A. et al. (2018). When is crossover desirable in cancer drug trials and when is it problematic?. Annals of oncology. pp. 1079-1081. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Haslam, A. et al. (2018). When is crossover desirable in cancer drug trials and when is it problematic?. Annals of oncology. pp. 1079-1081. [Online].